Coherus BioSciences Reports Fourth Quarter and Year End

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results

REDWOOD CITY, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS ), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.

2014 Highlights:

  • CHS-1701 (pegfilgrastim (Neulasta®) biosimilar): completed Phase 1 351(a) (novel biologic) study and transitioning to a 351(k) (biosimilar) approval pathway. In March 2015, the Company initiated a pivotal study, which, if positive, could support the filing of a 351(k) biologics license application (BLA) in the fourth quarter of 2015 or first quarter of 2016. An additional immunogenicity study is planned in healthy volunteers pursuant to this BLA and is projected to be concluded in 2015 to support submission of the BLA.
  • CHS-1420 (adalimumab (HUMIRA®) biosimilar): met the primary endpoint in a pivotal clinical pharmacokinetic similarity study that compared CHS-1420 to HUMIRA® in healthy subjects in August 2014.
  • CHS-0214 (etanercept (Enbrel®) biosimilar): initiated Phase 3 clinical studies in rheumatoid arthritis and in psoriasis.
  • Received milestone payments totaling $70.3 million under existing collaboration with Baxter Healthcare Corporation (Baxter) in 2014.
  • Closed initial public offering of 6,803,702 shares of common stock at $13.50 per share in November 2014, of which net proceeds were approximately $80.2 million.

"2014 was a strong year for Coherus in both clinical and financial accomplishments. The Company initiated several BLA enabling studies and is on track to file its first BLA with CHS-1701 in the next 12 months," said Denny Lanfear, president and chief executive officer of Coherus. "Additionally, our initial public offering created a foundation for completing the development of our three lead biosimilar product candidates."

Fourth Quarter 2014 Financial Results

Total revenue for the fourth quarter 2014 was $6.5 million, as compared to $1.2 million in the fourth quarter of 2013. The increase over the same period in 2013 was due to the recognition of Baxter collaboration revenue.

Research and development (R&D) expenses for the fourth quarter 2014 were $26.9 million compared with $9.2 million for the same period in 2013. Increases in R&D expenses were mainly attributable to an increase in program costs associated with the advancement of Coherus' late-stage clinical product candidates, CHS-0214 and CHS-1701, as well as increased personnel expenses.

General and administrative (G&A) expenses for the fourth quarter 2014 were $6.2 million, compared to $2.5 million for the same period in 2013. Increases in G&A expenses were mainly attributable to increased employee-related expenses and increased legal and accounting services in support of being a public company.

Net loss attributable to Coherus for the fourth quarter 2014 was $29.1 million, or $1.47 per share, compared to $14.6 million, or $3.68 per share, for the same period in 2013.

Fiscal Year 2014 Financial Results

Total revenue for the fiscal year 2014 was $31.1 million, as compared to $2.8 million in 2013. The increase over the same period in 2013 was due to the recognition of Baxter collaboration revenue.

Research and development (R&D) expenses were $78.2 million compared with $31.3 million in 2013. Increases in R&D expenses were mainly attributable to an increase in program costs associated with the advancement of Coherus' late-stage clinical product candidates, CHS-0214, CHS-1420 and CHS-1701, as well as increased personnel expenses.

General and administrative (G&A) expenses were $17.6 million, compared to $7.5 million in 2013. Increases in G&A expenses were mainly attributable to increased employee-related expenses and increased legal and accounting services in support of being a public company.

Net loss attributable to Coherus was $87.1 million, or $10.64 per share, compared to $53.6 million, or $16.10 per share, in 2013.

Cash and cash equivalents totaled $150.4 million as of December 31, 2014, compared to $39.6 million as of December 31, 2013.

Anticipated Near Term Milestones

  • CHS-1701 (pegfilgrastim biosimilar): file 351(k) BLA in U.S. in the fourth quarter of 2015 or the first quarter of 2016.
  • CHS-1420 (adalimumab biosimilar): initiate pharmacokinetic (PK) bioequivalence bridging study in 2015 with Phase 3 drug material; initiate Phase 3 clinical study in psoriasis late in the first half of 2015; file BLA in U.S. in second half of 2016.
  • CHS-0214 (etanercept biosimilar): continue Phase 3 clinical studies in rheumatoid arthritis and in psoriasis; file MAA in E.U. in 2016.

Conference Call Information

When: March 23, 2015, 1:30 p.m. PT
Dial-in: 844-452-6826 (domestic) or 765-507-2587 (international)
Conference ID: 5132313
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register.
The webcast of the conference call will be available for replay through April 6, 2015.

About Coherus BioSciences, Inc.

Coherus is a leading pure-play, global biosimilar company with a focus on developing products for the major regulated markets. Composed of a team of industry veterans with decades of experience in bringing biologics to market, our goal is to become a worldwide leader in the biosimilar market by leveraging our biologics platform in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus possesses late stage clinical products and commercialization partnerships with multinational pharmaceutical companies in Europe and Asia.

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com .

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus' plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including Coherus' expectations regarding its ability to advance its CHS-0214, CHS-1420 and CHS-1701 biosimilar drug candidates, file BLAs for CHS-1420 and CHS-1701 in the U.S. and file an MAA for CHS 0214 in the E.U. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the Securities and Exchange Commission on March 23, 2015, and its future periodic reports to be filed with the Securities and Exchange Commission.

Enbrel® and Neulasta® are registered trademarks of Amgen Inc.

HUMIRA® is a registered trademark of AbbVie Inc.

Coherus BioSciences, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
 
  Three Months Ended Year Ended
  December 31, December 31,
  2014 2013 2014 2013
  (unaudited)    
Revenue:        
Collaboration and license revenue - related party  $ 448  $ 506  $ 1,893  $ 2,025
Collaboration and license revenue  5,313  726  28,481  726
Other revenue  732  —   732  —
Total revenue  6,493  1,232  31,106  2,751
Operating expenses:        
Research and development  26,867  9,222  78,224  31,279
General and administrative  6,186  2,497  17,564  7,465
Total operating expenses  33,053  11,719  95,788  38,744
Loss from operations  (26,560)  (10,487)  (64,682)  (35,993)
Interest expense  —  (3,301)  (3,900)  (5,293)
Other expense, net  (2,463)  (803)  (18,595)  (12,349)
Net loss  (29,023)  (14,591)  (87,177)  (53,635)
Net (income) loss attributable to non-controlling interest  (111)  —   44  — 
Net loss attributable to Coherus  $ (29,134)  $ (14,591)  $ (87,133)  $ (53,635)
         
Net loss per share attributable to Coherus, basic and diluted  $ (1.47)  $ (3.68)  $ (10.64)  $ (16.10)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted  19,841,728  3,965,466  8,186,529  3,332,020
 
Coherus BioSciences, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
 
  December 31, December 31,
  2014 2013
     
Assets    
Cash and cash equivalents  $ 150,392  $ 39,554
Other assets  36,829  7,893
Total assets  $ 187,221  $ 47,447
Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)    
Deferred revenue  62,699  42,850
Other liabilities  57,765  46,979
Convertible preferred stock  —  54,695
Total stockholders' equity (deficit)  66,757  (97,077)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)  $ 187,221  $ 47,447

Susanna Chau Investor Relations Coherus BioSciences, Inc. +1 (650) 649-3577

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 10

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antonio Filosa Takes the Helm as CEO of Stellantis N.V.

Updated Category News Views 335

Antonio Filosa Appointed as Stellantis N.V. Chief Executive Officer Stellantis N.V., a prominent player in the global automotive arena, has officially announced the appointment of Antonio Filosa as its new Chief Executive Officer. Filosa, who has amassed over 25 years of experience within the automotive sector, currently holds the position of Chief Operating Officer for...

Continue Reading
Understanding the Edwards Lifesciences Legal Landscape

Updated Category News Views 278

Understanding Recent Legal Issues for Investors In the world of investment, understanding legal implications can often feel overwhelming, especially when a company faces a class action lawsuit. Edwards Lifesciences Corporation, a name recognized for its innovative heart valve technologies, currently finds itself embroiled in legal battles that could shape its future and...

Continue Reading
Arrive Home and FormFree Join Forces to Enhance Homeownership Access

Updated Category News Views 155

Arrive Home Partners with FormFree for Innovative Solutions The innovative collaboration between Arrive Home and FormFree aims to transform the landscape of homeownership for many borrowers facing challenges due to limited credit histories. This partnership is particularly significant as it opens doors for those who have previously been overlooked by traditional credit...

Continue Reading
Verizon's $20 Billion Acquisition: A Strategic Expansion Ahead

Updated Category News Views 76

Verizon Announces Major Acquisition of Frontier Communications Verizon has recently made headlines by announcing a significant acquisition deal with Frontier Communications. This all-cash transaction, valued at $20 billion, underscores Verizon's dedication to substantially expanding its fiber network. Details of the Acquisition According to the proposed terms, Verizon...

Continue Reading
MoxiWorks Enhances Innovation Timeline with New Leadership and Funding

Updated Category News Views 174

MoxiWorks Enhances Innovation Timeline with New Leadership and Funding Funding from private equity and brokerage partners, along with new leadership, is set to transform MoxiWorks, a leading provider of sales and marketing software in the real estate sector. With substantial capital secured from its ownership group, which includes Vector Capital, Howard Hanna Real Estate...

Continue Reading